Fee Information:

There is no fee for this educational activity.

---

Faculty

Barbara Gilchrest, M.D.
Department of Dermatology
609 Albany Street - J507
Boston, MA 02118

---

Learning Objectives:

Upon completion of this educational activity, participants should be able to:
-review the pathophysiology and prognostic import of actinic keratosis (AKs)
-review the mechanism of action of photodynamic therapy using aminolevutinic acid (ALA-PDT)
-compare ALA-PDT to other current AK therapies; risks, benefits, cost
-appropriately use ALA-PDT for patients who will benefit and I na ;manner that will maximize their benefit.

---

Accreditation:

MD/DO:
This activity is sponsored by the North American Center for Continuing Medical Education (NACCME). NACCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NACCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies.

---

Target Audience:

Dermatologists

---

Faculty Disclosures:
All those with control over the content of continuing education programs sponsored by NACCME are expected to disclose to the meeting audience any real or apparent conflicts of interest related to the content of their presentation. It is not assumed that these financial interests or affiliations will have an adverse impact on presentations; they are simply noted here to fully inform participants.

Dr. Gilchrest has disclosed that she has received grant/research support, is a consultant and scientific advisor to Dusa Pharmaceuticals.

---

Commercial Supporter: This activity is supported by an educational grant from Dusa

---

Sponsor: North American Center for Continuing Medical Education (logo).